NEW YORK, Oct. 10 – Qiagen said on Wednesday that it has received an exclusive license to market and distribute Kreatech Biotechnology’s ULS labeling technologies in combination with its resonance light scattering products.
In addition, Qiagen acquired non-exclusive rights to develop and sell ULS products for labeling and detecting nucleic acids and proteins in microarray experiments.
Qiagen, of Venlo, the Netherlands, said it would market these products with its nucleic acid sample separation and purification products and biomolecule detection technologies. The company also said that it would work with Kreatech to develop new applications and specialized products.
Qiagen did not disclose the financial terms of the deal.
Kreatech, based in Amsterdam, develops diagnostics and other life-science products.